MetaCap

Alterity Therapeutics (ATHE) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed Serina Therapeutics (SER) over the past year, losing 56.7% versus a loss of 71.9%. Over five years, ATHE leads with a -85.4% price change compared with -95.6% for SER. Serina Therapeutics is the larger company by market cap ($29.8 million vs $29.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%SER-71.93%
+75%-2%-79%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%SER-96.03%
+46%-28%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus SER key metrics
MetricATHESER
Share price$1.52$1.12
Market cap$29.02M$29.76M
1-day change-8.16%-6.67%
YTD return-50.65%-41.45%
1-year return-56.70%-71.93%
5-year return-85.38%-95.64%
EPS (TTM)$-0.90$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)—$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$5.89$4.26
52-week low$1.52$1.06
Distance from 52-week high-74.19%-73.71%
Analyst consensusnonenone
Avg. price target upside+771.71%+748.21%
Average volume89.63K68.98K
Shares outstanding19.09M26.57M
Employees1116
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATHE has outperformed SER by 15.2 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

ATHE vs SER FAQ

Which is bigger, Alterity Therapeutics or Serina Therapeutics?

Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $29.02M for Alterity Therapeutics (ATHE).

Which stock has performed better over the past year, ATHE or SER?

ATHE returned -56.70% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons